EHA 2021: Latest in immunotherapy for R/R multiple myeloma

OncoAlert and ecancer ASCO roundup - Day 4 and 5

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML

CLL14: Venetoclax plus obinutuzumab in untreated CLL

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Highlights from ASCO 2021

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma

ASCO 2021: Latest on PARPi and other treatments for mCRPC